| answer text |
<p>The Accelerated Access Collaborative (AAC) is interested in identifying and supporting
strategically important products that will have the biggest impact on patient health
outcomes and/or the delivery of National Health Service services. This may include
those which help control hospital-acquired infections.</p><p>The AAC has already had
made significant progress towards getting the best innovations to patients quicker
and at a better cost for the NHS.</p><p>Since 2018, NHS England has been supporting
SecurAcath and Plus Sutures, products designed to reduce infection rates, on the Innovation
and Technology Payment programme. SecurAcath is a device to secure catheters that
reduces the infection risk for patients with a peripherally inserted central catheter
and has benefited over 80,000 patients. Seven trusts with higher than 4% surgical
site infection rates have adopted Plus Sutures, a triclosan coated suture, with more
trusts to be supported this year.</p><p> </p><p><strong> </strong></p><p><strong>
</strong></p>
|
|
